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term follow-up in the TOF group, as well as the group
undergoing replacement of the previous RV-PA conduit. As
a result, we have favored the PTFE monocusp in both these
patient groups. Growth of the RVOT or eventual fibrocol-
lagenous incorporation of the PTFE leaflet may limit long-
term function of the monocusp in some patients. The PTFE
monocusp valve can be expected to retain adequate function
in the early-to-mid postoperative period with the only anti-
coagulant being low-dose aspirin (80 mg per day).
The decision to insert a biologic valved conduit or upsize
the PTFE monocusp patch was left up to the individual
surgeon and depended on the availability of a suitable
conduit. When a pulmonary homograft conduit was the only
conduit available, we were more likely to up-size the RVOT
with a second PTFE monocusp patch because we thought it
would be more durable than the other available conduits at
that time. With the introduction of the bovine jugular ve-
nous valved conduit (Contegra) in 2001 for clinical trial, we
have selectively used the Contegra in some patients who
require conduit revision or replacement to see whether the
degree of mid-to-late regurgitation is less with the Contegra
as compared with the monocusp valve outflow patch.23
The current study has the limitations of a retrospective
review and has no concurrent control group. Furthermore,
magnetic resonance imaging and more refined 2-dimensional
and even 3-dimensional echocardiographic studies would
have provided additional valuable data regarding evaluation
of RV function and dimensions as well as the PTFE mono-
cusp valve mechanics. Exercise testing and assessment of
volume of oxygen uptake would better evaluate the func-
tional benefits of this and other RVOT reconstruction tech-
niques. Nevertheless, PTFE monocusp valve reconstruction
of the RVOT is a safe, effective, and durable technique for
the mid term in the majority of patients and may delay or
obviate the need to insert a homograft or xenograft valve in
late follow-up. Continued use and long-term follow-up in-
cluding magnetic resonance imaging and exercise testing is
necessary to further demonstrate the value of this technique.
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Discussion
Dr Gordon Cohen (Seattle, Wash). Dr Brown, congratulations on
an interesting study, and thank you for sharing your excellent
results for this technique with us. The work you presented today
represents just one of the many contributions that you and your
group have made to our understanding of how to best reconstruct
the RVOT in a variety of different congenital defects. After re-
viewing your study, I have three questions for you.
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First, in the patients who required more than one PTFE mono-
cusp valve, what was the cause of failure and the median and mean
time to replacement? In addition, how did you choose in this group
of patients whether they would have repeat PTFE monocusp valve
replacement versus an RV-PA conduit?
Second, 15% of the patients had implantation of the PTFE
monocusp after RV-PA conduit. Oftentimes when homograft con-
duits fail, they exhibit shrinkage and calcification. Your own data
suggested that there was a mean gradient of 78 mm Hg in these
gradients consistent with shrinkage, calcification, or outgrowth.
How did you decide which patients with previous artery to PA
conduits would benefit from a PTFE monocusp valve in this
group?
Third, in your slide listing indications for PTFE monocusp
redo, you listed 10 patients with trace-to-mild PI as the reason.
Many of the valved conduits that we use have trace-to-mild PI
immediately after they are placed and the chest is closed. Why
would trace-to-mild PI of the PTFE monocusp or any other valve
other than for the reason of infection ever be an indication for
redo?
Dr Brown. Thank you, Dr Cohen. Those are all excellent
questions. To answer your first question, in patients who under-
went more than one PTFE monocusp, the cause of failure in almost
all situations, as pointed out in the curves, was PI. Only a handful
of patients had stenosis.
The second part of that is, how did you choose in which
patients you would repeat a PTFE monocusp and in which ones
would you use a conduit? To answer that question, if they previ-
ously had a conduit, we were not going to put in a second
homograft conduit because we know a second homograft conduit
fails faster than the first one. Therefore, if a patient had a failed
conduit we would put in a PTFE monocusp and then roof that over
with another PTFE patch. That is how we decided. However, after
2001, when the Contegra conduit came along, we had a choice of
either doing a PTFE monocusp reconstruction of that RVOT or
putting in a Contegra conduit. I have to admit our results with the
Contegra conduit look pretty promising thus far, and we are
leaning in that direction in those whose initial repairs have failed.
To answer your second question, in the 15% of patients who
had PTFE monocusp after RVOT conduits, the answer is almost
the same. We continue to try to use the PTFE monocusp in patients
in whom it makes sense, but when we have a conduit now that is
as good as the Contegra conduit, we are inclined to use more
Contegras when a reoperation is necessary. We usually reserve the
PTFE monocusp for primary repairs.
Finally, you are absolutely right about the patients with trace
PI. That is never an indication for replacement of a conduit or a
reconstruction of the RVOT. We just listed those in the slide.
Those were the few patients who had significant stenosis. They
also had mild PI, but we listed those diagnoses separately. We did
not reoperate on patients with trace PI because we know that
almost all pulmonary valves, pulmonary conduits, have some
leakage early in the postoperative period.
DOCTOR. I would like your comment on a couple issues.
Obviously, this is a big issue for congenital heart surgeons. We are
replacing the RVOT weekly in our patients. The issue that I have
seen, though, is that over the past few years our indications for
reinterventions seemed to be changed. Can you comment about
that over the time frame of your study?
Second, we are on the verge of these readily deployable per-
cutaneous valve replacements that are probably going to be most
successful in the pulmonary outflow tract first before they are
deployed in other regions. Does that influence your current recon-
struction? In other words, if a 20-year-old patient is referred to
you, what kind of valve replacement do you do so that he or she
can be set up for subsequent percutaneous valve replacements?
Dr Brown. Those are both excellent questions. First of all, the
way we are deciding to intervene has to do with magnetic reso-
nance imaging. We are studying all of our patients who have
dilated RVs with magnetic resonance images, comparing the end-
diastolic volumes of the RV with the LV. Right now we are using
the Emory formula. If the RV volume is twice that of the LV, we
know it is time to intervene even though the patient is asymptom-
atic because atrial arrhythmias are likely to develop shortly after
those ventricles begin to dilate more than that and significant
tricuspid insufficiency is likely to occur. We would like to try to
intervene before they get those arrhythmias or the tricuspid valve
begins to fail. We are doing more RVOT reconstructions than we
have ever done in the past and we, like you, are doing them
weekly.
Percutaneous pulmonary valves are available in Europe now.
More than 110 have been used in London. Yes, we would prefer to
put a nonstented valve in the pulmonary position initially because
that will make it easier for a stent-deployed valve later on. We are
using more stentless valves in the adult patient population. I think
there is a little caution here, though, that at least the Contegra
conduit is what they use for the stent-mounted valves for the
pulmonary position. At least there are some early data that suggest
when those valves are mounted inside a stent they do not last
nearly as long as if they were surgically implanted. We are going
to have to watch that patient population very closely, because I
know that at least 10% of the stent-mounted valves have failed
within a 2-year period and we do not see that with a surgically
inserted Contegra valve. We will need a little more follow-up.
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